Japan Medical Dynamic Marketing, INC. (JMD) fair value: what the stock is really worth
As of Oct 26, 2026: fair value (intrinsic value) of Japan Medical Dynamic Marketing, INC. stock €1.24, price €3.38, upside -63.3%, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 21, 2026.
How to read this chart
60‑month range €2.38 – €16.75 · fair‑value band €0.9300 – €1.54 · the €3.38 price screens above the €1.24 fair value. Dashed = 300-day average. As of Oct 21, 2026.
Follow Japan Medical Dynamic Marketing in your weekly email
Every Wednesday you see whether Japan Medical Dynamic Marketing is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Japan Medical Dynamic Marketing, INC. develops, manufactures, imports, and sells medical devices in Japan and the United States.
Show moreShow less
The company provides trauma devices, including nails, screws, plates, and other products surgically implanted in the fracture site used in surgery to treat femoral neck fractures, most often suffered by the elderly, and other fractures from auto-related and other accidents; joint prostheses, which replaces natural joints and restores functions damaged or lost due to disease or injury, such as hip and knee joint products; spinal fixation devices to fix spinal instability directly through corrective surgery; and artificial bones that are used to fill gaps in bone defects caused by bone fractures or bone tumors.
It offers its products to doctors, medical institutions, and hospitals. The company was incorporated in 1973 and is headquartered in Shinjuku, Japan.
Stock analysis
Japan Medical Dynamic Marketing, INC. (JMD) currently trades at €3.38, while our model-based Fair Value estimate is €1.24, 63.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of €3.15 per share, and 2 of the 16 models we run sit above the €3.38 price.
Bear case: the Earnings-Based group reads lowest at €0.3900, and 14 of the 16 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €0.9300 (bear) to €1.54 (bull), the price of €3.38 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Japan Medical Dynamic Marketing, INC. reported revenue of ¥23.9B in FY2026 versus ¥19.2B in FY2022, a compound +5.7%/yr. Reported net income was ¥263M in FY2026, compounding −40.8%/yr from FY2022.
Key figures
Market cap €89.1M Micro · P/E ratio 56.4 · P/S ratio 0.62 · EPS (TTM) €0.0600 · Dividend yield 2.9% · Net margin −0.9% · Return on equity −0.9% · Return on assets (EBIT) 5.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 36% below its 52-week high and 46% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −63%, JMD screens richer than that median.
Fair Value models
Bear€0.9300Fair Value €1.24Bull€1.54
Price €3.38 · Upside -63.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Start year 2021 (pandemic). Over 10 years: +6.3% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−31.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−34.2%
Dividend (yield on the price)2.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−34.2% vs −13.6%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 2%
Compare Japan Medical Dynamic Marketing, INC. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 328 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−63.3% · Bottom 25%
Profitability
Return on assets0.7% · Below median
Net margin (12 months)−0.9% · Below median
Operating margin (12 months)−9.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−10.1% · Bottom 25%
Dividend yield (12 months)2.9% · Above median
Balance sheet
Debt / equity0.03× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)56.4× · Priciest 25%
P/B0.60× · Cheapest 25%
P/S (12 months)0.66× · Cheapest 25%
EV/EBITDA8.7× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 8
FUTURE (revenue growth)0· sector 32
PAST (return on equity)0· sector 16
HEALTH (low debt)99· sector 98
DIVIDEND (yield)57· sector 37
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Japan Medical Dynamic Marketing, INC. Fair Value". https://www.fairvalue-calculator.com/stock/JMD
Frequently asked questions
Is Japan Medical Dynamic Marketing, INC. (JMD) overvalued or undervalued?
As of Oct 21, 2026, our model estimates a fair value of €1.24 versus a price of €3.38, about −63% upside (overvalued).
What is the fair value of JMD?
Our model-based fair value for Japan Medical Dynamic Marketing, INC. is €1.24 (as of Oct 21, 2026), built from audited fundamentals. The current price: €3.38.
What is the quality score of JMD?
Japan Medical Dynamic Marketing, INC. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Japan Medical Dynamic Marketing, INC. (JMD)?
Our model-based price target is the fair value of €1.24 (as of Oct 21, 2026) from 16 valuation models. Cautious scenario €0.9300, optimistic scenario €1.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Japan Medical Dynamic Marketing, INC. stock forecast for 2026?
Our models put fair value at €1.24, about −63% upside versus a price of €3.38 (overvalued). Cautious scenario €0.9300, optimistic scenario €1.54. The calculation is refreshed regularly with new filings.
What is the revenue of Japan Medical Dynamic Marketing, INC. (JMD)?
Japan Medical Dynamic Marketing, INC. reported trailing-twelve-month revenue of about ¥23.3B (latest available figure, as of Oct 21, 2026).
Does Japan Medical Dynamic Marketing, INC. pay a dividend?
Japan Medical Dynamic Marketing, INC. currently shows a dividend yield of 2.85% relative to its recent price (as of Oct 21, 2026).
What is the intrinsic value of Japan Medical Dynamic Marketing, INC. (JMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Japan Medical Dynamic Marketing, INC. it is €1.24 per share (as of Oct 21, 2026), against a price of €3.38. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Japan Medical Dynamic Marketing, INC. stock overvalued or undervalued in 2026?
As of Oct 21, 2026, JMD trades above its calculated fair value: price €3.38, fair value €1.24, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of JMD?
No. The price is what the market pays today (€3.38); the fair value is what the company's own numbers justify (€1.24). For Japan Medical Dynamic Marketing, INC. the two are €2.14 per share apart. That gap is exactly why we show both numbers side by side.
How much is Japan Medical Dynamic Marketing, INC. worth?
The market values Japan Medical Dynamic Marketing, INC. at about €89.1M (market capitalisation, as of Oct 21, 2026). Per share that is €3.38; our models calculate a fair value of €1.24 per share.
What do the bullish and bearish scenarios say about JMD?
Our models span a range for Japan Medical Dynamic Marketing, INC.: cautious scenario €0.9300, base €1.24, optimistic €1.54 per share (as of Oct 21, 2026, price €3.38). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of JMD?
Japan Medical Dynamic Marketing, INC. trades at a price-to-earnings ratio of 56.4 (as of Oct 21, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €1.24 is built from several models across several years. Other multiples: P/B 0.6, P/S 0.7, EV/EBITDA 8.7.
How solid is the balance sheet of Japan Medical Dynamic Marketing, INC. (JMD)?
Balance-sheet figures for Japan Medical Dynamic Marketing, INC. (as of Oct 21, 2026): return on equity −0.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is JMD from its 52-week high?
Japan Medical Dynamic Marketing, INC. trades at €3.38, about 36% below its 52-week high of €5.30 and 46% above the low of €2.32 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €1.24 is for.
Which stocks are comparable to Japan Medical Dynamic Marketing, INC.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Japan Medical Dynamic Marketing, INC. stock attractive at the current price?
The data as of Oct 21, 2026: price €3.38, calculated fair value €1.24 (−63%), Quality Score 47/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of JMD calculated?
We run Japan Medical Dynamic Marketing, INC. through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €1.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Japan Medical Dynamic Marketing, INC. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Japan Medical Dynamic Marketing, INC. (JMD)?
The closing price on Oct 26, 2026 was €3.38. Our model-based fair value is €1.24, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Japan Medical Dynamic Marketing, INC. right now?
The price sits above even our optimistic bull case (€1.54). The favourable scenario is already priced in. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Japan Medical Dynamic Marketing, INC.
How large is the market capitalisation of Japan Medical Dynamic Marketing, INC. (JMD)?
The market capitalisation of Japan Medical Dynamic Marketing, INC. is €89.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Japan Medical Dynamic Marketing, INC. (JMD)?
The price-to-sales ratio of Japan Medical Dynamic Marketing, INC. is 0.62 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Japan Medical Dynamic Marketing, INC. (JMD)?
Earnings per share at Japan Medical Dynamic Marketing, INC. are €0.0600 (price ÷ EPS = P/E 56.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Japan Medical Dynamic Marketing, INC. (JMD)?
The dividend yield of Japan Medical Dynamic Marketing, INC. is 2.9% (payout 161%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Japan Medical Dynamic Marketing, INC. (JMD)?
The net margin of Japan Medical Dynamic Marketing, INC. is −0.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Japan Medical Dynamic Marketing, INC. (JMD)?
The return on equity (ROE) of Japan Medical Dynamic Marketing, INC. is −0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Japan Medical Dynamic Marketing, INC. (JMD)?
On an EBIT basis the return on assets of Japan Medical Dynamic Marketing, INC. is 5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Japan Medical Dynamic Marketing, INC. (JMD)?
The operating margin of Japan Medical Dynamic Marketing, INC. is −9.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Japan Medical Dynamic Marketing, INC. (JMD)?
Revenue at Japan Medical Dynamic Marketing, INC. is growing −10.1% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Japan Medical Dynamic Marketing, INC. (JMD)?
Earnings per share at Japan Medical Dynamic Marketing, INC. are growing −43.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Japan Medical Dynamic Marketing, INC. (JMD) generate?
The free cash flow of Japan Medical Dynamic Marketing, INC. is −¥1.8B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Japan Medical Dynamic Marketing, INC. (JMD) carry?
The net debt of Japan Medical Dynamic Marketing, INC. is ¥2.5B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Japan Medical Dynamic Marketing, INC. in the live analysis
One click puts Japan Medical Dynamic Marketing, INC. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 21, 2026